

SUMMARY OF PRODUCT CHARACTERISTICS

Zinnat Tablets 125 mg **Zinnat Tablets 250 mg** **Zinnat Tablets 500 mg**

1. NAME OF THE MEDICINAL PRODUCT

Zinnat Tablets 125 mg
Zinnat Tablets 250 mg
Zinnat Tablets 500 mg

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Zinnat Tablets 125 mg

Each tablet contains 125 mg cefuroxime (as axetil).

Zinnat Tablets 250 mg

Each tablet contains 250 mg cefuroxime (as axetil).

Zinnat Tablets 500 mg

Each tablet contains 500 mg cefuroxime (as axetil).

Excipient(s) with known effect:

Each 125mg tablet contains:

0.00152 mg sodium benzoate (E211)

Methyl parahydroxybenzoate (E218)

Propyl parahydroxybenzoate (E216)

Each 250mg tablet contains:

0.00203 mg sodium benzoate (E211)

Methyl parahydroxybenzoate (E218)

Propylparahydroxybenzoate (E216)

Each 500mg tablet contains:

0.00506 mg sodium benzoate (E211)

Methyl parahydroxybenzoate (E218)

Propyl parahydroxybenzoate (E216)

For the full list of excipients, see section 6.1

3. PHARMACEUTICAL FORM

Film-coated tablet (tablet)

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Zinnat is indicated for the treatment of the infections listed below in adults and children from the age of 3 months (see sections 4.4 and 5.1).

- Acute streptococcal tonsillitis and pharyngitis.
- Acute bacterial sinusitis.
- Acute otitis media.
- Acute exacerbations of chronic bronchitis.
- Cystitis.
- Pyelonephritis.
- Uncomplicated skin and soft tissue infections.
- Treatment of early Lyme disease.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2 Posology and method of administration

Posology

The usual course of therapy is seven days (may range from five to ten days).

Table 1. Adults and children (≥ 40 kg)

Indication	Dosage
Acute tonsillitis and pharyngitis, acute bacterial sinusitis	250 mg twice daily
Acute otitis media	500 mg twice daily
Acute exacerbations of chronic bronchitis	500 mg twice daily
Cystitis	250 mg twice daily
Pyelonephritis	250 mg twice daily
Uncomplicated skin and soft tissue infections	250 mg twice daily
Lyme disease	500 mg twice daily for 14 days (range of 10 to 21 days)

Table 2. Children (< 40 kg)

Indication	Dosage
Acute tonsillitis and pharyngitis, acute bacterial sinusitis	10 mg/kg twice daily to a maximum of 125 mg twice daily
Children aged two years or older with otitis media or, where appropriate, with more severe infections	15 mg/kg twice daily to a maximum of 250 mg twice daily
Cystitis	15 mg/kg twice daily to a maximum of 250 mg twice daily
Pyelonephritis	15 mg/kg twice daily to a maximum of 250 mg twice daily for 10 to 14 days
Uncomplicated skin and soft tissue infections	15 mg/kg twice daily to a maximum of 250 mg twice daily
Lyme disease	15 mg/kg twice daily to a maximum of 250 mg twice daily for 14 days (10 to 21 days)

There is no experience of using Zinnat in children under the age of 3 months.

Cefuroxime axetil tablets and cefuroxime axetil granules for oral suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis (see section 5.2).

Renal impairment

The safety and efficacy of cefuroxime axetil in patients with renal failure have not been established.

Cefuroxime is primarily excreted by the kidneys. In patients with markedly impaired renal function it is recommended that the dosage of cefuroxime should be reduced to compensate for its slower excretion. Cefuroxime is effectively removed by dialysis.

Table 5. Recommended doses for Zinnat in renal impairment

Creatinine clearance	T _{1/2} (hrs)	Recommended dosage
≥30 ml/min/1.73 m ²	1.4–2.4	no dose adjustment necessary (standard dose of 125 mg to 500 mg given twice daily)
10-29 ml/min/1.73 m ²	4.6	standard individual dose given every 24 hours
<10 ml/min/1.73 m ²	16.8	standard individual dose given every 48 hours
During haemodialysis	2–4	a single additional standard individual dose should be given at the end of each dialysis

Hepatic impairment

There are no data available for patients with hepatic impairment. Since cefuroxime is primarily eliminated by the kidney, the presence of hepatic dysfunction is expected to have no effect on the pharmacokinetics of cefuroxime.

Method of administration

Oral use

Zinnat tablets should be taken after food for optimum absorption.

Zinnat tablets should not be crushed and are therefore unsuitable for treatment of patients who cannot swallow tablets. In children Zinnat oral suspension may be used.

Depending on the dosage, there are other presentations available.

4.3 Contraindications

Hypersensitivity to cefuroxime or to any of the excipients listed in section 6.1.

Patients with known hypersensitivity to cephalosporin antibiotics.

History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of betalactam antibacterial agent (penicillins, monobactams and carbapenems).

4.4 Special warnings and precautions for use

Hypersensitivity reactions

Special care is indicated in patients who have experienced an allergic reaction to penicillins or other beta-lactam antibiotics because there is a risk of cross-sensitivity. As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. In case of severe hypersensitivity reactions, treatment with cefuroxime must be discontinued immediately and adequate emergency measures must be initiated.

Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to cefuroxime, to other cephalosporins or to any other type

of beta-lactam agent. Caution should be used if cefuroxime is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.

Severe cutaneous adverse reactions (SCARS)

Severe cutaneous adverse reactions including: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS), which can be life-threatening or fatal, have been reported in association with cefuroxime treatment (see section 4.8).

At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, cefuroxime should be withdrawn immediately and an alternative treatment considered. If the patient has developed a serious reaction such as SJS, TEN or DRESS with the use of cefuroxime, treatment with cefuroxime must not be restarted in this patient at any time.

Jarisch-Herxheimer reaction

The Jarisch-Herxheimer reaction has been seen following cefuroxime axetil treatment of Lyme disease. It results directly from the bactericidal activity of cefuroxime axetil on the causative bacteria of Lyme disease, the spirochaete *Borrelia burgdorferi*. Patients should be reassured that this is a common and usually self-limiting consequence of antibiotic treatment of Lyme disease (see section 4.8).

Overgrowth of non-susceptible microorganisms

As with other antibiotics, use of cefuroxime axetil may result in the overgrowth of *Candida*. Prolonged use may also result in the overgrowth of other non-susceptible microorganisms (e.g. enterococci and *Clostridium difficile*), which may require interruption of treatment (see section 4.8).

Antibacterial agent-associated pseudomembranous colitis have been reported with nearly all antibacterial agents, including cefuroxime and may range in severity from mild to life threatening. This diagnosis should be considered in patients with diarrhoea during or subsequent to the administration of cefuroxime (see section 4.8). Discontinuation of therapy with cefuroxime and the administration of specific treatment for *Clostridium difficile* should be considered. Medicinal products that inhibit peristalsis should not be given (see section 4.8).

Interference with diagnostic tests

The development of a positive Coomb's Test associated with the use of cefuroxime may interfere with cross matching of blood (see section 4.8).

As a false negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase methods are used to determine blood/plasma glucose levels in patients receiving cefuroxime axetil.

Important information about excipients

This medicine contains:

0.00152 mg sodium benzoate in each 125 mg tablet

0.00203 mg sodium benzoate in each 250 mg tablet

0.00506 mg sodium benzoate in each 500 mg tablet

Zinnat tablets contain parabens which may cause allergic reactions (possibly delayed).

Zinnat tablets contains less than 1 mmol (23 mg) of sodium, that is to say essentially 'sodium free'.

4.5 Interactions with other medicinal products and other forms of interaction

Drugs which reduce gastric acidity may result in a lower bioavailability of cefuroxime axetil compared with that of the fasting state and tend to cancel the effect of enhanced absorption after food.

Cefuroxime axetil may affect the gut flora, leading to lower oestrogen reabsorption and reduced efficacy of combined oral contraceptives.

Cefuroxime is excreted by glomerular filtration and tubular secretion. Concomitant use of probenecid is not recommended. Concurrent administration of probenecid significantly increases the peak concentration, area under the serum concentration time curve and elimination half-life of cefuroxime.

Concomitant use with oral anticoagulants may give rise to increased INR.

4.6 Fertility, pregnancy and lactation

Pregnancy

There are limited data from the use of cefuroxime in pregnant women. Studies in animals have shown no harmful effects on pregnancy, embryonal or foetal development, parturition or postnatal development. Zinnat should be prescribed to pregnant women only if the benefit outweighs the risk.

Breastfeeding

Cefuroxime is excreted in human milk in small quantities. Adverse effects at therapeutic doses are not expected, although a risk of diarrhoea and fungus infection of the mucous membranes cannot be excluded. Breastfeeding might have to be discontinued due to these effects. The possibility of sensitisation should be taken into account. Cefuroxime should only be used during breastfeeding after benefit/risk assessment by the physician in charge.

Fertility

There are no data on the effects of cefuroxime axetil on fertility in humans. Reproductive studies in animals have shown no effects on fertility.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. However, as this medicine may cause dizziness, patients should be warned to be cautious when driving or operating machinery.

4.8 Undesirable effects

The most common adverse reactions are *Candida* overgrowth, eosinophilia, headache, dizziness, gastrointestinal disturbances and transient rise in liver enzymes.

The frequency categories assigned to the adverse reactions below are estimates, as for most reactions suitable data (for example from placebo-controlled studies) for calculating incidence were not available. In addition the incidence of adverse reactions associated with cefuroxime axetil may vary according to the indication.

Data from large clinical studies were used to determine the frequency of very common to rare undesirable effects. The frequencies assigned to all other undesirable effects (i.e. those occurring at $<1/10,000$) were mainly determined using post-marketing data and refer to a reporting rate rather than true frequency. Placebo-controlled trial data were not available. Where incidences have been calculated from clinical trial data, these were based on drug-related (investigator assessed) data. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Treatment related adverse reactions, all grades, are listed below by MedDRA body system organ class, frequency and grade of severity. The following convention has been utilised for

the classification of frequency: very common $\geq 1/10$; common $\geq 1/100$ to $< 1/10$, uncommon $\geq 1/1,000$ to $< 1/100$; rare $\geq 1/10,000$ to $< 1/1,000$; very rare $< 1/10,000$ and not known (cannot be estimated from the available data).

System organ class	Common	Uncommon	Not known
<u>Infections and infestations</u>	<i>Candida overgrowth</i>		<i>Clostridium difficile overgrowth</i>
<u>Blood and lymphatic system disorders</u>	eosinophilia	positive Coomb's test, thrombocytopenia, leukopenia (sometimes profound)	haemolytic anaemia
Cardiac disorders			Kounis syndrome
<u>Immune system disorders</u>			drug fever, serum sickness, anaphylaxis, Jarisch-Herxheimer reaction
<u>Nervous system disorders</u>	headache, dizziness		
<u>Gastrointestinal disorders</u>	diarrhoea, nausea, abdominal pain	vomiting	pseudomembranous colitis (see section 4.4)
<u>Hepatobiliary disorders</u>	transient increases of hepatic enzyme levels		jaundice (predominantly cholestatic), hepatitis
<u>Skin and subcutaneous tissue disorders</u>		skin rashes	urticaria, pruritus, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (exanthematic necrolysis) (see Immune system disorders), angioneurotic oedema Drug Reactions with Eosinophilia and Systemic Symptoms (DRESS)

Description of selected adverse reactions

Cephalosporins as a class tend to be absorbed onto the surface of red cells membranes and react with antibodies directed against the drug to produce a positive Coombs' test (which can interfere with cross-matching of blood) and very rarely haemolytic anaemia.

Transient rises in serum liver enzymes have been observed which are usually reversible.

Paediatric population

The safety profile for cefuroxime axetil in children is consistent with the profile in adults.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form

<https://sideeffects.health.gov.il>

4.9 Overdose

Overdose can lead to neurological sequelae including encephalopathy, convulsions and coma. Symptoms of overdose can occur if the dose is not reduced appropriately in patients with renal impairment (see sections 4.2 and 4.4).

Serum levels of cefuroxime can be reduced by haemodialysis and peritoneal dialysis.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: antibacterials for systemic use, second-generation cephalosporins, ATC code: J01DC02

Mechanism of action

Cefuroxime axetil undergoes hydrolysis by esterase enzymes to the active antibiotic, cefuroxime.

Cefuroxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.

Mechanism of resistance

Bacterial resistance to cefuroxime may be due to one or more of the following mechanisms:

- hydrolysis by beta-lactamases; including (but not limited to) by extended-spectrum beta-lactamases (ESBLs), and AmpC enzymes that may be induced or stably derepressed in certain aerobic Gram-negative bacteria species;
- reduced affinity of penicillin-binding proteins for cefuroxime;
- outer membrane impermeability, which restricts access of cefuroxime to penicillin binding proteins in Gram-negative bacteria;
- bacterial efflux pumps.

Organisms that have acquired resistance to other injectable cephalosporins are expected to be resistant to cefuroxime.

Depending on the mechanism of resistance, organisms with acquired resistance to penicillins may demonstrate reduced susceptibility or resistance to cefuroxime.

Cefuroxime axetil breakpoints

Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:

Microorganism	Breakpoints (mg/L)	
	<u>S</u>	<u>R</u>
<i>Enterobacteriaceae</i> ^{1,2}	≤8	>8
<i>Staphylococcus</i> spp.	Note ³	Note ³
<i>Streptococcus</i> A, B, C and G	Note ⁴	Note ⁴
<i>Streptococcus pneumoniae</i>	≤0.25	>0.5
<i>Moraxella catarrhalis</i>	≤0.125	>4
<i>Haemophilus influenzae</i>	≤0.125	>1
Non-species related breakpoints ¹	IE ⁵	IE ⁵

¹ The cephalosporin breakpoints for *Enterobacteriaceae* will detect all clinically important resistance mechanisms (including ESBL and plasmid mediated AmpC). Some strains that produce beta-lactamases are susceptible or intermediate to 3rd or 4th generation cephalosporins with these breakpoints and should be reported as found, i.e. the presence or absence of an ESBL does not in itself influence the categorization of susceptibility. In many areas, ESBL detection and characterization is recommended or mandatory for infection control purposes.

² Uncomplicated UTI (cystitis) only (see section 4.1).

³ Susceptibility of staphylococci to cephalosporins is inferred from the methicillin susceptibility except for ceftazidime and cefixime and ceftibuten, which do not have breakpoints and should not be used for staphylococcal infections.

⁴ The beta-lactam susceptibility of beta-haemolytic streptococci groups A, B, C and G is inferred from the penicillin susceptibility.

⁵ insufficient evidence that the species in question is a good target for therapy with the drug. An MIC with a comment but without an accompanying S or R-categorization may be reported.

S=susceptible, R=resistant

Microbiological susceptibility

The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of cefuroxime axetil in at least some types of infections is questionable.

Cefuroxime is usually active against the following microorganism *in vitro*.

Commonly susceptible species
<u>Gram-positive aerobes:</u> <i>Staphylococcus aureus</i> (methicillin susceptible)* <i>Coagulase negative staphylococcus</i> (methicillin susceptible) <i>Streptococcus pyogenes</i> <i>Streptococcus agalactiae</i>
<u>Gram-negative aerobes:</u> <i>Haemophilus influenzae</i> <i>Haemophilus parainfluenzae</i> <i>Moraxella catarrhalis</i>
<u>Spirochaetes:</u> <i>Borrelia burgdorferi</i>
Microorganisms for which acquired resistance may be a problem
<u>Gram-positive aerobes:</u> <i>Streptococcus pneumoniae</i>
<u>Gram-negative aerobes:</u> <i>Citrobacter freundii</i> <i>Enterobacter aerogenes</i> <i>Enterobacter cloacae</i> <i>Escherichia coli</i> <i>Klebsiella pneumoniae</i> <i>Proteus mirabilis</i> <i>Proteus spp.</i> (other than <i>P. vulgaris</i>) <i>Providencia spp.</i>
<u>Gram-positive anaerobes:</u> <i>Peptostreptococcus spp.</i> <i>Propionibacterium spp.</i>
<u>Gram-negative anaerobes:</u> <i>Fusobacterium spp.</i> <i>Bacteroides spp.</i>
Inherently resistant microorganisms
<u>Gram-positive aerobes:</u> <i>Enterococcus faecalis</i> <i>Enterococcus faecium</i>
<u>Gram-negative aerobes:</u> <i>Acinetobacter spp.</i> <i>Campylobacter spp.</i> <i>Morganella morganii</i> <i>Proteus vulgaris</i> <i>Pseudomonas aeruginosa</i> <i>Serratia marcescens</i>
<u>Gram-negative anaerobes:</u> <i>Bacteroides fragilis</i>
<u>Others:</u> <i>Chlamydia spp.</i> <i>Mycoplasma spp.</i> <i>Legionella spp.</i>

* All methicillin-resistant *S. aureus* are resistant to cefuroxime.

5.2 Pharmacokinetic properties

Absorption

After oral administration cefuroxime axetil is absorbed from the gastrointestinal tract and rapidly hydrolysed in the intestinal mucosa and blood to release cefuroxime into the circulation. Optimum absorption occurs when it is administered shortly after a meal.

Following administration of cefuroxime axetil tablets peak serum levels (2.1 mcg/ml for a 125 mg dose, 4.1 mcg/ml for a 250 mg dose, 7.0 mcg/ml for a 500 mg dose and 13.6 mcg/ml for a 1000 mg dose) occur approximately 2 to 3 hours after dosing when taken with food. The rate of absorption of cefuroxime from the suspension is reduced compared with the tablets, leading to later, lower peak serum levels and reduced systemic bioavailability (4 to 17% less). Cefuroxime axetil oral suspension was not bioequivalent to cefuroxime axetil tablets when tested in healthy adults and therefore is not substitutable on a milligram-per-milligram basis (see section 4.2). The pharmacokinetics of cefuroxime is linear over the oral dosage range of 125 to 1000 mg. No accumulation of cefuroxime occurred following repeat oral doses of 250 to 500 mg.

Distribution

Protein binding has been stated as 33 to 50% depending on the methodology used. Following a single dose of cefuroxime axetil 500 mg tablet to 12 healthy volunteers, the apparent volume of distribution was 50 L (CV%=28%). Concentrations of cefuroxime in excess of the minimum inhibitory levels for common pathogens can be achieved in the tonsilla, sinus tissues, bronchial mucosa, bone, pleural fluid, joint fluid, synovial fluid, interstitial fluid, bile, sputum and aqueous humor. Cefuroxime passes the blood-brain barrier when the meninges are inflamed.

Biotransformation

Cefuroxime is not metabolised.

Elimination

The serum half-life is between 1 and 1.5 hours. Cefuroxime is excreted by glomerular filtration and tubular secretion. The renal clearance is in the region of 125 to 148 ml/min/1.73 m².

Special patient populations

Gender

No differences in the pharmacokinetics of cefuroxime were observed between males and females.

Elderly

No special precaution is necessary in the elderly patients with normal renal function at dosages up to the normal maximum of 1 g per day. Elderly patients are more likely to have decreased renal function; therefore, the dose should be adjusted in accordance with the renal function in the elderly (see section 4.2).

Paediatrics

In older infants (aged >3 months) and in children, the pharmacokinetics of cefuroxime are similar to that observed in adults.

There is no clinical trial data available on the use of cefuroxime axetil in children under the age of 3 months.

Renal impairment

The safety and efficacy of cefuroxime axetil in patients with renal failure have not been established. Cefuroxime is primarily excreted by the kidneys. Therefore, as with all such antibiotics, in patients with markedly impaired renal function (i.e. $Cl_{cr} < 30$ ml/minute) it is recommended that the dosage of cefuroxime should be reduced to compensate for its slower excretion (see section 4.2). Cefuroxime is effectively removed by dialysis.

Hepatic impairment

There are no data available for patients with hepatic impairment. Since cefuroxime is primarily eliminated by the kidney, the presence of hepatic dysfunction is expected to have no effect on the pharmacokinetics of cefuroxime.

Pharmacokinetic/pharmacodynamic relationship

For cephalosporins, the most important pharmacokinetic-pharmacodynamic index correlating with *in vivo* efficacy has been shown to be the percentage of the dosing interval (%T) that the unbound concentration remains above the minimum inhibitory concentration (MIC) of cefuroxime for individual target species (i.e. %T>MIC).

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology, repeated dose toxicity, genotoxicity and toxicity to reproduction and development. No carcinogenicity studies have been performed; however, there is no evidence to suggest carcinogenic potential.

Gamma glutamyl transpeptidase activity in rat urine is inhibited by various cephalosporins, however the level of inhibition is less with cefuroxime. This may have significance in the interference in clinical laboratory tests in humans.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet Core

Microcrystalline cellulose
Croscarmellose sodium, Type A
Hydrogenated vegetable oil
Sodium lauril sulphate
Silica Colloidal Anhydrous

Film Coat

Hypromellose
Propylene glycol
Methyl parahydroxybenzoate
Propyl parahydroxybenzoate
Opaspray White M-1-7120J (Titanium dioxide, Hypromellose , Industrial Methylated Spirits, Sodium benzoate, Purified water).

6.2 Incompatibilities

A positive Coombs' test has been reported during treatment with cephalosporins - this phenomenon can interfere with cross-matching of blood.

6.3 Shelf life

The expiry date of the product is indicated on the packaging materials

6.4 Special precautions for storage

Store in the original pack in a dry place below 30°C.

6.5 Nature and Contents of Container

Zinnat Tablets 125 mg, Zinnat Tablets 250 mg:

Aluminium foil blister pack.
Pack size 10 or 50

Zinnat Tablets 500 mg:

Aluminium foil blister pack.
Pack size 2, 10 or 50

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. LISENCE HOLDER AND IMPORTER NAME AND ADDRESS

Sandoz Pharmaceuticals Israel Ltd., P.O.Box 9015, , Tel Aviv, Israel

8. LISENCE NUMBERS

Zinnat Tablets 125 mg: 041-40-25801

Zinnat Tablets 250 mg: 041-42-25802

Zinnat Tablets 500 mg: 041-41-25803

Revised in January 2025

ZINN TAB API JAN2025 V1